CSCJC3456

Main objectives: Phase Ia: Evaluate the safety and tolerability of CSCJC3456 tablets in patients with advanced malignant solid tumors; determine dose-limiting toxicity (DLT) and maximum tolerated dose (MTD); provide recommended doses and dosing regimens for Phase Ib clinical trials. Phase Ib: Preliminary evaluation of the anti-tumor activity of CSCJC3456 tablets in target patients with advanced malignant solid tumors. Secondary objectives: Phase Ia: Study the PK characteristics of CSCJC3456 and its main metabolites (such as CSCJC3456-desmethyl, etc.) after single/multiple administrations; Preliminary observation of the effectiveness of CSCJC3456 tablets in the treatment of advanced malignant solid tumors. Phase Ib: Further evaluate the effectiveness and PK characteristics of CSCJC3456 tablets in target patients with advanced solid tumors, evaluate safety, tolerability, and the relationship between corresponding tumor markers and clinical efficacy. Exploratory purpose: To evaluate the changes in pharmacodynamic (PD) indicators of CSCJC3456 tablets in the treatment of patients with advanced malignant solid tumors; to evaluate the relationship between CSCJC3456 plasma concentration and QT interval; Phase Ia: to identify possible metabolites in plasma after single/multiple administration of CSCJC3456 tablets; Phase Ib: to explore the possible correlation between tumor-related genotype-based molecular biomarkers and clinical outcomes.